Vilya, Inc.
- Biotech or pharma, therapeutic R&D
Vilya is a cutting-edge computational biotechnology company, co-founded a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D. and by ARCH Venture Partners.
At Vilya, we are creating a novel class of medicines to precisely target disease biology. Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space within cyclic peptides to design new molecular structures not found in nature.
We aim to boldly leverage cutting edge computing to change how we design new medicines, and to ultimately cure diseases.